---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-043238"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:37:36.066415+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Allarity Q1 net loss $3.8M; Phase 2 stenoparib benefit, equity $15M, Nasdaq compliance

## Summary
- Phase 2 stenoparib trial concluded early due to clear clinical benefits: tumor shrinkage and long-term disease stability in ovarian cancer; preparing follow-on trial with FDA intent.
- Cash balance $14M, stockholders' equity $15M, exceeding Nasdaq $2.5M minimum; seeking formal compliance confirmation.
- Net loss $3.8M for Q1 2024 vs $3.4M Q1 2023; R&D expenses $2.2M (+$0.7M YoY), G&A $2.1M (flat).
- Regained Nasdaq bid price compliance after reverse stock split; capital structure simplified: all variable-priced warrants exercised, Series A Preferred converted.
- Withdrew Form S-1 registration; focus solely on stenoparib, deprioritizing IXEMPRA and dovitinib.

## SEC filing metadata
- accession: 0001213900-24-043238
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/0001213900-24-043238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/ea0206157-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-043238
- JSON: https://secwatch.observer/filing/0001213900-24-043238.json
- Plain text: https://secwatch.observer/filing/0001213900-24-043238.txt

## Key facts
- Earnings Releases
  Allarity Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income -$3.8 million.
  - Period: first quarter ended March 31, 2024
  - Net income: -$3.8 million
  - Result: reported results
  source text: Net loss was $3.8 million for the quarter ended March 31, 2024, compared to $3.4 million for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/0001213900-24-043238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.